Moody’s upgrades Merck’s credit rating to “A3” with stable
Moody’s Investors Service raised Merck’s long-term issuer rating to “A3” from “Baa1” with stable outlook.
Moody’s noted in its report: “The upgrade takes into account the group’s well-executed cost-efficiency initiatives, which have recently contributed to a stronger cash conversion.”
“After Merck received the ‘A’ rating from Standard & Poor’s in May, we are proud of this second upgrade in such a short period of time,” said Matthias Zachert, Merck’s Chief Financial Officer. “It is a clear recognition and acknowledgement that Merck is on the right track.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.